Newland Pharmaceutical Co., Ltd. (SHE:301277)

Market Cap	5.49B
Revenue (ttm)	761.64M
Net Income (ttm)	174.28M
Shares Out	392.08M
EPS (ttm)	0.44
PE Ratio	31.61
Forward PE	n/a
Dividend	0.29 (2.04%)
Ex-Dividend Date	Apr 16, 2025

Volume	13,081,360
Average Volume	25,974,778
Open	14.08
Previous Close	14.22
Day's Range	13.87 - 14.16
52-Week Range	8.27 - 18.38
Beta	0.62
RSI	45.77
Earnings Date	Aug 13, 2025

About Newland Pharmaceutical

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, l...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,042
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301277

Financial Performance

In 2024, Newland Pharmaceutical's revenue was 726.44 million, an increase of 11.51% compared to the previous year's 651.44 million. Earnings were 173.63 million, an increase of 9.22%.